The authors comment with interest on the systematic review and meta-analysis of clopidogrel versus aspirin for the secondary prevention of coronary artery disease by Marco Valgimigli et al. The review included seven randomized trials with data on 28,982 patients. It found a lower incidence of major adverse cardiovascular or cerebrovascular events (MACCE) with clopidogrel versus aspirin—929 events (2.61 per 100 patient-years) versus 1062 events (2.99 per 100 patient-years). Most of the studies were open and funded by industry. All studies were assessed as having a low risk of bias.